Assenagon Asset Management S.A. Has $70.13 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Assenagon Asset Management S.A. lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 55.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 397,772 shares of the medical research company's stock after purchasing an additional 142,170 shares during the period. Assenagon Asset Management S.A. owned about 0.23% of IQVIA worth $70,127,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. American National Bank & Trust bought a new position in shares of IQVIA in the 1st quarter worth approximately $26,000. ST Germain D J Co. Inc. raised its holdings in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new position in IQVIA during the fourth quarter valued at $39,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA during the 4th quarter valued at $44,000. Finally, Zions Bancorporation N.A. grew its position in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on the company. JPMorgan Chase & Co. dropped their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Wall Street Zen cut shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. HSBC cut IQVIA from a "buy" rating to a "hold" rating and reduced their price objective for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Citigroup reissued a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Finally, Robert W. Baird reduced their price target on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Trading Down 1.6%

IQV stock traded down $2.55 during midday trading on Friday, hitting $156.59. The stock had a trading volume of 737,130 shares, compared to its average volume of 1,610,603. The company's 50-day moving average price is $147.33 and its 200 day moving average price is $177.98. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market cap of $27.09 billion, a PE ratio of 20.90, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business's revenue was up 2.5% on a year-over-year basis. During the same period last year, the business earned $2.54 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.